We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
38 hedge funds and large institutions have $302M invested in Entrada Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more capital invested
Capital invested by funds: $243M → $302M (+$59M)
3.82% less ownership
Funds ownership: 82.81% → 78.99% (-3.8%)
21% less funds holding
Funds holding: 48 → 38 (-10)
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Holders
38
Holders Change
-10
Holders Change %
-20.83%
% of All Funds
0.64%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
8
Increased
5
Reduced
15
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 2 |
CA
CHI Advisors
New York
|
+$1.24M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$1.22M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$979K |
| 5 |
Millennium Management
New York
|
+$580K |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.64M |
| 2 |
BlackRock
New York
|
-$2.89M |
| 3 |
SG
StepStone Group
La Jolla,
California
|
-$958K |
| 4 |
State Street
Boston,
Massachusetts
|
-$918K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$576K |
